Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.21.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Condensed Consolidated Statements of Operations and Comprehensive Loss        
Revenues $ 765 $ 96 $ 1,880 $ 518
Cost of goods sold 493 86 1,275 404
Gross profit 272 10 605 114
Operating expenses:        
Research and development (related party of $0, $0, $0 and $97) 2,162 1,095 6,892 2,990
General and administrative (related party of $491, $316, $1,394 and $941) 5,313 2,979 15,385 8,198
Total operating expenses 7,475 4,074 22,277 11,188
Operating loss (7,203) (4,064) (21,672) (11,074)
Other income (expense):        
Interest expense (related party of $610, $616, $1,836 and $1,851) (612) (616) (1,841) (1,851)
Interest income 152 4 183 12
Royalty income 1   3 9
Total other income (expense) (459) (612) (1,655) (1,830)
Consolidated net loss (7,662) (4,676) (23,327) (12,904)
Net loss attributable to noncontrolling interest 1   4 3
Net loss attributable to iBio, Inc. (7,661) (4,676) (23,323) (12,901)
Deemed dividends - down round of Series A Preferred and Series B Preferred     0 (21,560)
Preferred stock dividends – iBio CMO Tracking Stock (64) (65) (195) (196)
Net loss available to iBio, Inc. stockholders (7,725) (4,741) (23,518) (34,657)
Comprehensive loss:        
Consolidated net loss (7,662) (4,676) (23,327) (12,904)
Other comprehensive loss - unrealized loss on securities (16)   (36)  
Other comprehensive loss - foreign currency translation adjustments (1) (2) 0 (2)
Comprehensive loss $ (7,678) $ (4,677) $ (23,363) $ (12,906)
Loss per common share attributable to iBio, Inc. stockholders - basic and diluted $ (0.04) $ (0.06) $ (0.12) $ (0.74)
Weighted-average common shares outstanding - basic and diluted 215,539 79,917 188,493 47,018